

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(1) REDESIGNATION OF DIRECTOR AND (2) APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**” and each, a “**Director**”) of China NT Pharama Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the following changes in composition of the Board.

(1) REDESIGNATION OF DIRECTOR

Ms. Chin Yu (“**Ms. Chin**”) will be re-designated from an executive Director to a non-executive Director with effect from 15 January 2024. Ms. Chin, co-founder of the Group. She has been an executive Director since February 2015 and responsible for the Group’s daily operations. For more biographical details of Ms. Chin, please refer to our company website.

Ms. Chin has entered into a letter of appointment with no fix term. The appointment of Ms. Chin also subject to retirement by rotation and re-election at the general meetings of the Company in accordance with the articles of association of the Company. Pursuant to the letter of appointment, Ms. Chin does not receive any Director’s fee or remuneration from the Company.

As at the date of this announcement, within the meaning of Part XV of the Securities and Futures Ordinance, Ms. Chin has interest in respect of 50,000 shares of the Company, which is jointly owned by Mr. Ng and Ms. Chin, and an aggregate of 402,892,000 shares of the Company, which is beneficially owned by Golden Base Investment Limited, a Company of which Mr. Ng and Ms Chin are the controlling shareholders. Ms. Chin also has personal interest in 4,000,000 shares in the Company.

Save as disclosed above, Ms. Chin does not have any relationship with other Directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) or controlling shareholders (as defined in the Listing Rules) of the Company. Ms. Chin does not have any interest in the shares or underlying shares of the Company or any of its associated corporations which is required to be disclosed under Part XV of the SFO. Ms. Chin did not hold any directorship in other listed public companies in the last three years, and she is not holding any other position with the Company or any of its subsidiaries.

In addition, there is no other matters that needs to be brought to the attention of the shareholders of the Company nor any information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

(2) APPOINTMENT OF EXECUTIVE DIRECTOR

Ms. Ng, Anna Ching Mei (“**Ms. Ng**”) has been appointed as an executive Director of the Company with effect from 15 January 2024. She is the daughter of Mr. Ng and Ms. Chin, a executive Director, co-founder of the Group and the substantial shareholder of the Company. She also is niece of Dr. Qian Wei, a non-executive Director. The biographical details of Ms. Ng is set out below:

Ms. Ng, age 25, graduated from MSc Healthcare at University College London. She has 3 years working experience on laboratory experimental research with professor in Medicine and Biological Information Engineering department of Northeastern University Shenyang China. Ms. Ng has published 2 journals on Chinese Academy of Sciences and delcared the exclusive right by The China national patent office of these journals. Ms. Ng has ample experience in medicine and biological information engineering.

Ms. Ng has entered into a letter of appointment with the Company pursuant to which she agreed to act as an executive Director and she will be subject to rotational retirement and re-election requirements at annual general meetings pursuant to the bye-laws of the Company. The emoluments of Ms. Ng will be determined by the Remuneration Committee and the Board after taking into account the prevailing market situation and her duties and responsibilities within the Company.

The Board would like to take this opportunity to express its warmest welcome to Ms. Ng for joining the Board.

As at the date of this announcement, save as disclosed above, Ms. Ng does not have any relationship with other Directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) or controlling shareholders (as defined in the Listing Rules) of the Company. Ms. Ng does not have any interest in the shares or underlying shares of the Company or any of its associated corporations which is required to be disclosed under Part XV of the SFO.

As at the date of this announcement, Ms. Ng did not hold any directorship in other listed public companies in the last three years, and she is not holding any other position with the Company or any of its subsidiaries.

In addition, there is no other matters that needs to be brought to the attention of the shareholders of the Company nor any information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 15 January 2024

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Mr. Ng Ming Kwan.